Cancer

News

Merck & Co's Keytruda outperforms chemo in MSI-High colorect...

Merck & Co’s Keytruda (pembrolizumab) immunotherapy has outperformed standard of care in untreated colorectal cancer with certain mutations, offering patients a single-agent therapy opt

News

NICE recommends Roche's Tecentriq in ES-SCLC following price...

NICE has said that Roche’s Tecentriq (atezolizumab) plus chemotherapy should be funded by the NHS as an option for untreated extensive-stage small-cell lung cancer (ES-SCLC) in second draft

Views & Analysis

Secondary-effects-of-COVID-19-on-the-pharma-healthcare-and-patients

Secondary effects of COVID-19 on pharma, healthcare and pati...

Reminders of the impact of the COVID-19 pandemic on our healthcare system, economy, and day-to-day lives are everywhere.

News

AZ/Merck & Co take on Clovis as FDA approves prostate cancer...

The FDA has approved AstraZeneca and Merck & Co’s Lynparza (olaparib) in metastatic castration-resistant prostate cancer, just days after the regulator gave the nod for Clovis’ PARP-cla

News